Related Experiment Video
Updated: May 21, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
Efficacy of alternate-day versus everyday dosing of atorvastatin
Sushobhan Pramanik1, Asoke Kumar Das, Milan Chakrabarty
1Department of Pharmacology, R.G. Kar Medical College, Kolkata, West Bengal, India. sushobhan.pramanik@gmail.com
Insights
Alternate-day atorvastatin dosing is as effective and safe as daily dosing for hyperlipidemia. This provides a comparable, cost-effective treatment option for managing cholesterol levels.
Area of Science:
- Pharmacology and Therapeutics
- Cardiovascular Medicine
- Lipid Metabolism
Background:
- Atorvastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, exhibits a prolonged duration of action.
- Hyperlipidemia management often involves statin therapy, with atorvastatin being a commonly prescribed option.
Purpose of the Study:
- To compare the efficacy and safety of alternate-day versus daily dosing of atorvastatin.
- To evaluate atorvastatin's effectiveness in treating hyperlipidemia under different dosing frequencies.
Main Methods:
- Prospective, open-label, crossover study involving 40 hyperlipidemia patients.
- Patients received 20 mg atorvastatin either daily or on alternate days for 12 weeks, followed by a 4-week washout and then the alternative regimen.
- Plasma lipid profiles (LDL-C, TC) and liver enzymes (ALT, AST) were monitored throughout the study.
Main Results:
- Both daily and alternate-day atorvastatin regimens significantly reduced LDL-C and TC compared to baseline.
- No statistically significant differences in LDL-C and TC reduction were observed between the two dosing groups at 6 and 12 weeks.
- Both treatment regimens were well-tolerated by patients.
Conclusions:
- Alternate-day atorvastatin dosing is a viable and effective alternative to daily administration for hyperlipidemia.
- This dosing strategy offers comparable efficacy and safety, presenting a potentially more cost-effective treatment option.
Background:
Atorvastatin has a longer duration of action than other hydroxymethylglutaryl coenzyme A reductase inhibitors.
Objectives:
The objective was to evaluate the efficacy of alternate day vs. daily dosing of atorvastatin for the treatment of hyperlipidemia.
Materials And Methods:
In this prospective, open label, crossover study, 40 patients with plasma low-density cholesterol (LDL-C) of more than 130 mg/dl and total cholesterol (TC) more than 200 mg/dl were recruited. After baseline tests, they were randomly allocated to two groups. Group A received 20 mg atorvastatin on alternate days and group B received 20 mg atorvastatin daily for 12 weeks. After 4 weeks of washout period, the groups were crossed over to the other treatment regimen for another 12 weeks. Fasting plasma lipid profile and serum alanine transaminase (ALT) and aspartate transaminase (AST) were measured for both groups at 6(th), 12(th), 16(th), 22(nd), and 28(th) weeks. Results were pooled across the periods and data between the two groups were compared using unpaired t-test.
Results:
Among the 40 enrolled subjects, 38 completed the study. Both treatment regimens significantly reduced LDL-C and TC compared to baseline. There was no statistically significant difference between the two groups in terms of reduction of plasma LDL-C and TC at 6 and 12 weeks of treatment. Both the regimens were well tolerated.
Conclusion:
Alternate-day treatment with atorvastatin is comparable in efficacy and safety to the established daily treatment regimen, thus being a cost effective alternative.
Related Concept Videos
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Dosage Regimen: Multiple Oral Dosage
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Time Course of Drug Effect
Atherosclerosis III: Management